Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients

Fathy Mona M.; Taleb Mohamed E. Abo; El Hawary Mohamed S.; Nabih Mona I.; Aref Wael M.; Makhlouf Manal M.

首页> 外文期刊>Cytokine >Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients

【24h】

Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients

机译：评估白介素28B基因型作为聚乙二醇干扰素加利巴韦林联合治疗HCV感染埃及患者反应的预测指标

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and aim: Single nucleotide polymorphisms (SNPs) of interleukin 28B (IL28B) gene is associated with spontaneous clearance and variable response to combined therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV) in chronic hepatitis C virus (HCV) infected patients. This study aimed at assessing the value of IL28B rs8099917 gene polymorphism in predicting sustained virological response (SVR) among HCV infected Egyptian patients treated with PEG-IFN and RBV.

机译：背景与目的：白细胞介素28B（IL28B）基因的单核苷酸多态性（SNPs）与聚乙二醇干扰素（PEG-IFN）和利巴韦林（RBV）联合治疗慢性丙型肝炎病毒（HCV）感染的自发清除和可变反应有关耐心。这项研究旨在评估IL28B rs8099917基因多态性在预测接受PEG-IFN和RBV治疗的HCV感染的埃及患者中的持续病毒学应答（SVR）中的价值。

著录项

来源
《Cytokine》 |2015年第2期|共5页
作者
Fathy Mona M.; Taleb Mohamed E. Abo; El Hawary Mohamed S.; Nabih Mona I.; Aref Wael M.; Makhlouf Manal M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类细胞生物学;
关键词
Interleukin 28B; Genotype; Real Time PCR; Interferon lambda;

机译：白介素28B基因型实时荧光定量PCR干扰素;

相似文献

外文文献
中文文献
专利

1. Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients [J] . Fathy Mona M., Taleb Mohamed E. Abo, El Hawary Mohamed S., Cytokine . 2015,第2期

机译：评估白介素28B基因型作为聚乙二醇干扰素加利巴韦林联合治疗HCV感染埃及患者反应的预测指标
2. Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. [J] . DAvolio A, Ciancio A, Siccardi M, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2011,第6期

机译：利巴韦林的药代动力学和白介素28B加上细胞色素P450 27B1单核苷酸多态性可预测感染1/4型丙型肝炎病毒的患者对聚乙二醇干扰素/利巴韦林治疗的反应。
3. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy [J] . LiuC.-H., LiangC.-C., LiuC.-J., Antiviral therapy . 2012,第3期

机译：白细胞介素28B的基因多态性和病毒因素有助于确定哪些HCV基因型1患者受益于24周聚乙二醇化干扰素加利巴韦林治疗
4. HCV-related Factors but not HIV-Related Factors at Baseline Predict the Response to Treatment With Peginterferon alfa-2a (40KD) (PEGASYS) Plus Ribavirin (COPEGUS) in Patients With HCV/HIV Co-infection: Predictor Analysis From the APRICOT Study [C] . D. Cooper, F.J. Torriani, M. Rodriguez Torres International AIDS Conference . 2004

机译：HCV相关因素但基线上没有艾滋病毒相关因素预测与HCV / HIV共感染患者的Peginterferon Alfa-2a（40kd）（Pegasys）（Pegasys）加利巴韦林（Copegus）对治疗的反应：来自杏研究的预测因素分析
5. Serum and Fecal Biomarkers Predict Response to Infliximab Therapy in Pediatric Patients with Inflammatory Bowel Disease [D] . Kim, Jochebed. 2020

机译：血清和粪便生物标志物预测对炎症肠病小儿患者的英夫利昔单抗疗法的反应
6. The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis [O] . Marwa Khairy, Rabab Fouad, Mahassen Mabrouk, 2013

机译：数据挖掘分析白介素28b基因多态性对慢性HCV基因型4感染的埃及患者对聚乙二醇干扰素联合利巴韦林治疗的病毒学应答的影响
7. Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-α and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients [O] . de Castellarnau, Montserrat, Aparicio, Ester, Parera, Mariona, 2012

机译：解释可以更好地预测HCV / HIV-1合并感染患者对聚乙二醇化干扰素-α和利巴韦林治疗的反应的白介素28B变异体

Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients

摘要

著录项

相似文献

相关主题

期刊订阅